A snapshot of cancer vaccine development
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
Newly discovered bacterial communication system aids antimicrobial resistance
SMART researchers find the enzyme RlmN, which directly senses chemical and environmental stresses, can be targeted in drug development.
A new vision for ultrasound imaging
Ultrasound research specialist and 2023 MIT Excellence Award winner Nicole Henning adapts ultrasound technology for more sensitive, less invasive imaging for disease modeling.
MIT researchers to lead a new center for continuous mRNA manufacturing
A pilot-scale system, enabled by an $82 million award from the FDA, aims to accelerate the development and production of mRNA technologies.
Generative AI imagines new protein structures
“FrameDiff” is a computational tool that uses generative AI to craft new protein structures, with the aim of accelerating drug development and improving gene therapy.
A novel combination therapy counters antibiotic-resistant Mycobacterium abscessus infections
SMART researchers combine rifaximin and clarithromycin to effectively restore the latter drug's efficacy.
Putting the STING into cancer immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
Funding to Daniel Anderson’s lab will advance research on new delivery technology for RNA vaccines and therapies
The global health care company Sanofi is providing $25 million to advance RNA research.
Speeding up drug discovery with diffusion generative models
MIT researchers built DiffDock, a model that may one day be able to find new drugs faster than traditional methods and reduce the potential for adverse side effects.
A shot in the arm
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics.
New nanoparticles can perform gene editing in the lungs
Using these RNA-delivery particles, researchers hope to develop new treatments for cystic fibrosis and other lung diseases.
A novel combination therapy for treating vancomycin-resistant bacterial infections
Developed at SMART, the therapy stimulates the host immune system to more effectively clear bacterial infections and accelerate infected wound healing.
A new control switch could make RNA therapies easier to program
Using this approach, researchers hope to deliver therapeutic RNA molecules selectively to cancer cells or other target cells.
3 Questions: Mriganka Sur on the research origins of the first approved drug to treat Rett syndrome
On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.
New purification method could make protein drugs cheaper
MIT engineers find specialized nanoparticles can quickly and inexpensively isolate proteins from a bioreactor.